Skip to main content
    S

    Spero Therapeutics Inc (SPRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.05 (-5.35%)

    Market Cap: $58.26M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Spero Therapeutics Inc (SPRO) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Spero Therapeutics (SPRO) trades at 11.1x trailing earnings and 1.3x sales. Its P/S of 1.3x is below its 5-year median of 1.6x.

    Current Multiples

    MultipleValue
    P/E (trailing)11.1x
    Forward P/EN/A
    Price to sales1.3x
    Price to book70.6x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 77.6% below 5.8x and its P/B is 3261.9% above 2.1x.

    MultipleCurrent5-year median10-year median
    P/S1.3x1.6x5.8x
    P/B70.6x1.4x2.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 107 to 108 months (10-year).

    Valuation History

    Over the 9 year ends shown, its P/S ranged from 0.8x in 2023 to 45.9x in 2020.

    Year endPriceP/EP/SP/B
    2025$2.3319.3x2.0x2.3x
    2024$1.03N/A1.2x1.2x
    2023$1.472.8x0.8x0.7x
    2022$1.73N/A1.5x1.1x
    2021$16.01N/A26.6x5.8x
    2020$19.39N/A45.9x4.0x
    2019$9.62N/A9.4x2.5x
    2018$6.15N/A25.1x0.9x
    2017$11.75N/A6.1x1.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About SPRO

    What is SPRO's price to sales ratio?

    Spero Therapeutics has a price to sales ratio of 1.3x.